RESUMO
OBJECTIVES: Sexual networks are known to structure sexually transmitted infection (STI) transmission among men who have sex with men (MSM). We sought to estimate the risks of STI diagnosis for various partnership types within these networks. METHODS: Our cross-sectional survey analysed data from 1376 MSM screened for a partner management intervention in Lima, Peru. Participants were tested for HIV, syphilis, gonorrhoea (NG) and chlamydia (CT) and completed surveys on their demographics, sexual identity/role, HIV status, partnership types and sexual network from the prior 90 days. χ2 and Wilcoxon rank-sum tests compared participants without an STI to those diagnosed with (1) syphilis, (2) NG and/or CT (NG/CT) and (3) syphilis and NG/CT coinfection (coinfection). RESULTS: 40.8% (n=561/1376) of participants were diagnosed with an STI (syphilis: 14.9%, NG/CT: 16.4%, coinfection: 9.5%). 47.9% of all participants were living with HIV and 8.9% were newly diagnosed. A greater proportion of participants with syphilis and coinfection were living with HIV (73.5%, p<0.001; 71.0%, p<0.001) compared with those with NG/CT (47.8%) or no STI (37.8%). Participants with syphilis more often reported sex-on-premises venues (SOPVs) as the location of their last sexual encounter (51.7%, p=0.038) while those with NG/CT tended to meet their last sexual partner online (72.8%, p=0.031). Respondents with coinfection were the only STI group more likely to report transactional sex than participants without an STI (31.3%, p=0.039). CONCLUSIONS: Sexual networks and partnership types of Peruvian MSM are associated with differential risks for STIs. Participants diagnosed with syphilis tended to meet single-encounter casual partners at SOPV, while MSM with NG/CT were younger and often contacted casual partners online. Coinfection had higher frequency of transactional sex. These findings suggest the potential importance of public health interventions through combined syphilis/HIV screening at SOPV, syphilis screening at routine clinic appointments for MSM living with HIV and directed advertisements and/or access to NG/CT testing through online platforms.
Assuntos
Chlamydia , Coinfecção , Gonorreia , Infecções por HIV , Minorias Sexuais e de Gênero , Infecções Sexualmente Transmissíveis , Sífilis , Masculino , Humanos , Gonorreia/epidemiologia , Gonorreia/diagnóstico , Sífilis/epidemiologia , Sífilis/diagnóstico , Homossexualidade Masculina , Peru/epidemiologia , Estudos Transversais , Coinfecção/epidemiologia , Infecções por HIV/epidemiologia , Infecções por HIV/diagnóstico , Infecções Sexualmente Transmissíveis/epidemiologia , Infecções Sexualmente Transmissíveis/diagnóstico , Parceiros SexuaisRESUMO
INTRODUCTION: Oral pre-exposure prophylaxis (PrEP) for HIV-1 infection is over 99% effective in protecting against HIV acquisition when used consistently and appropriately. However, PrEP uptake and persistent use remains suboptimal, with a substantial gap in utilization among key populations who could most benefit from PrEP. In Latin America specifically, there is poor understanding of barriers to PrEP uptake and persistence among transgender (trans) women. METHODS: In April-May 2018, we conducted qualitative interviews lasting 25-45 min as part of an end-of-project evaluation of TransPrEP, a pilot RCT that examined the impact of a social network-based peer support intervention on PrEP adherence among trans women in Lima, Peru. Participants in the qualitative evaluation, all adult trans women, included individuals who either (1) screened eligible to participate in the TransPrEP pilot, but opted not to enroll (n = 8), (2) enrolled, but later withdrew (n = 6), (3) were still actively enrolled at the time of interview and/or successfully completed the study (n = 16), or (4) were study staff (n = 4). Interviews were audio recorded and transcribed verbatim. Codebook development followed an immersion/crystallization approach, and coding was completed using Dedoose. RESULTS: Evaluation participants had a mean age of 28.2 years (range 19-47). When describing experiences taking PrEP, participant narratives highlighted side effects that spanned three domains: physical side effects, such as prolonged symptoms of gastrointestinal distress or somnolence; economic challenges, including lost income due to inability to work; and social concerns, including interpersonal conflicts due to HIV-related stigma. Participants described PrEP use within a broader context of social and economic marginalization, with a focus on daily survival, and how PrEP side effects negatively contributed to these stressors. Persistence was, in some cases, supported through the intervention's educational workshops. CONCLUSION: This research highlights the ways that physical, economic, and social side effects of PrEP can impact acceptability and persistence among trans women in Peru, amplifying and layering onto existing stressors including economic precarity. Understanding the unique experiences of trans women taking PrEP is crucial to informing tailored interventions to improve uptake and persistence.
Assuntos
Infecções por HIV , Profilaxia Pré-Exposição , Pesquisa Qualitativa , Pessoas Transgênero , Humanos , Peru , Feminino , Pessoas Transgênero/psicologia , Pessoas Transgênero/estatística & dados numéricos , Adulto , Infecções por HIV/prevenção & controle , Masculino , Adesão à Medicação/estatística & dados numéricos , Adesão à Medicação/psicologia , Projetos Piloto , Adulto Jovem , Fármacos Anti-HIV/uso terapêutico , Entrevistas como Assunto , Fatores Socioeconômicos , Pessoa de Meia-IdadeRESUMO
Background: Despite high rates of HIV transmission among men who have sex with men (MSM) in Lima, Peru, limited data exist on the sexual network characteristics or risk factors for secondary HIV transmission among MSM with uncontrolled HIV infection. We report the frequency of serodiscordant, condomless anal intercourse (CAI) and associated sexual network characteristics among MSM in Lima with detectable HIV viremia and compare to those with undetectable viremia. Methods: This cross-sectional analysis includes MSM who tested positive for HIV-1 during screening for a trial of partner management and STI control (June 2022-January 2023). Participants were tested for HIV, gonorrhoea, chlamydia, and syphilis, and completed questionnaires on their demographic characteristics, sexual identity and behaviour, sexual network structures and engagement in HIV care. Findings: Of 665 MSM, 153 (23%) had detectable (>200 copies/mL) viremia. 75% (499/662) of men living with HIV were previously diagnosed, with 94% (n = 469/499) reporting that they were on ART, and 93% (n = 436/469) virally suppressed. 96% (n = 147/153) of men with detectable viremia reported serodiscordant CAI with at least one of their last three sexual partners, and 74% (n = 106/144) reported the same with all three of their recent partners. In contrast, 62% (n = 302/489) of men with undetectable viral load reported serodiscordant CAI with all of their last three partners (p < 0.01). Interpretation: 23% of men living with HIV in Peru had detectable viremia, of whom almost all (96%) reported recent serodiscordant CAI. The primary gap in the HIV care cascade lies in awareness of HIV serostatus, suggesting that improved access to HIV testing could be a key prevention strategy in Peru. Funding: Funding for this study was provided by NIH/NIMH grants R01 MH118973 (PI: Clark) and R25 MH087222 (PI: Clark).
RESUMO
INTRODUCTION: HPTN 083 demonstrated the superiority of long-acting cabotegravir (CAB-LA) versus daily oral emtricitabine/tenofovir disoproxil fumarate (TDF/FTC) as pre-exposure prophylaxis (PrEP) among cisgender men and transgender women who have sex with men (MSM/TGW). HPTN 083 provided the first opportunity to understand experiences with injectable PrEP in a clinical trial. METHODS: Participants from two US sites (Chicago, IL and Atlanta, GA) and one international site (Rio de Janeiro, Brazil) were purposively sampled for individual qualitative interviews (N = 40), between November 2019 and March 2020, to explore trial experiences, barriers to adherence and other factors that may have impacted study implementation or outcomes. The blinded phase ended early due to efficacy; this analysis includes interviews conducted prior to unblinding with three groups defined by adherence (i.e. injection visit attendance): adherent (n = 27), non-adherent (n = 12) and early discontinuers (n = 1). Data were organized using NVivo software and analysed using content analysis. RESULTS: Participants (mean age: 27) were primarily cisgender MSM (90%) and Black/African American (60%). Reasons for trial enrolment and PrEP use included a preference for using HIV prevention medication versus treatment in the event of HIV acquisition; the ability to enhance health via study-related education and services; access to a novel, convenient HIV prevention product at no cost; and contributing to MSM/TGW communities through research. Participants contrasted positive experiences with study staff with their routine clinical care, and emphasized increased scheduling flexibility, thorough communication, non-judgemental counselling and open, affirming environments (e.g. compassion, less stigma) as adherence facilitators. Injection experiences were positive overall; some described early injection-related anxiety, which abated with time and when given some measure of control (e.g. pre-injection countdown), and minimal injection site discomfort. Some concerns and misperceptions about injectable PrEP were reported. Barriers to adherence, across all adherence categories, included structural factors (e.g. financial constraints, travel) and competing demands (e.g. work schedules). CONCLUSIONS: Respondents viewed injectable PrEP trial participation as a positive experience and a means of enhancing wellbeing. Study site flexibility and affirming clinic environments, inclusive of non-judgemental counselling, were key facilitators of adherence. To support injection persistence, interventions that address structural barriers and promote flexible means of injection delivery may be most effective.
Assuntos
Fármacos Anti-HIV , Infecções por HIV , Adesão à Medicação , Profilaxia Pré-Exposição , Humanos , Masculino , Profilaxia Pré-Exposição/métodos , Adesão à Medicação/estatística & dados numéricos , Infecções por HIV/prevenção & controle , Infecções por HIV/tratamento farmacológico , Feminino , Fármacos Anti-HIV/administração & dosagem , Fármacos Anti-HIV/uso terapêutico , Adulto , Pessoas Transgênero/psicologia , Homossexualidade Masculina , Adulto Jovem , Piridonas/administração & dosagem , Piridonas/uso terapêutico , Brasil , Injeções , Piridinas/administração & dosagem , Piridinas/uso terapêutico , Entrevistas como Assunto , Tenofovir/administração & dosagem , Tenofovir/uso terapêutico , Combinação Emtricitabina e Fumarato de Tenofovir Desoproxila/administração & dosagem , Combinação Emtricitabina e Fumarato de Tenofovir Desoproxila/uso terapêutico , Pessoa de Meia-Idade , DicetopiperazinasRESUMO
ABSTRACT Syndemic psychosocial and reproductive factors affecting women's retention in HIV care remain understudied. We analyzed correlates of non-retention in a cohort of women with HIV in Brazil from 2000-2015. Participants self-reported exposure to physical/sexual violence, illicit drug use, adolescent pregnancy, or induced abortion. Lifetime history of these psychosocial stressors were used to create a syndemic score based on the presence or absence of these conditions. All dichotomous variables were summed (range 0 to 4), with greater scores indicating more syndemic factors experienced. Logistic regression models identified predictors of non-retention, defined as < 2 HIV viral load or CD4 results within the first year of enrollment. Of 915 women, non-retention was observed for 18%. Prevalence of syndemic factors was adolescent pregnancy (53.2%), physical/sexual violence (38.3%), induced abortion (27.3%), and illicit drug use (17.2%); 41.2% experienced > 2 syndemic conditions. Syndemic scores of 2 and 3 were associated with non-retention, as well as low education, years with HIV and seroprevalent syphilis. Psychosocial and reproductive syndemics can limit women's retention in HIV care. Syphilis infection predicted non-retention and could be explored as a syndemic factor in future studies.
RESUMO
Introdução: O número de usuários da profilaxia pré-exposição (PrEP) no Brasil continua baixo, apesar do acesso gratuito pelo Sistema Único de Saúde. Exploramos as associações entre conhecimento sobre HIV e homonegatividade internalizada com o uso de PrEP entre homens que fazem sexo com homens (HSH) elegíveis para PrEP. Métodos: Brasileiros usuários do Hornet completaram uma pesquisa seccional online em fevereiro-março de 2020. Foram incluídos homens cis ≥18 anos, que reportaram sexo recente com homens e elegíveis para PrEP. O desfecho principal foi uso de PrEP, definido por: "Estou atualmente tomando PrEP." Os principais preditores incluíram escalas de Conhecimento em HIV/aids (HIV-KA) e de Reações à Homossexualidade (RHS); escores mais altos indicam maior conhecimento e maior homonegatividade internalizada, respectivamente. As escalas foram padronizadas para análise. Associações com uso da PrEP foram estimadas usando razões de chances ajustadas (aOR) com intervalos de confiança de 95% (IC95%). Resultados: Entre 2.398 HSH elegíveis para PrEP, 370 (15,4%) relataram o uso atual de PrEP. Maior conhecimento em HIV/AIDS foi associado a maior chance de uso de PrEP (aOR 1·70 [IC 95% 1·412·04], p < 0·001), e maior homonegatividade internalizada com menor chance de uso de PrEP (aOR 0·83 [95% IC 0·730·96], p = 0·010). Uso de PrEP foi menor entre HSH de 1824 vs. 40+ anos (aOR 0·43 [IC95%:0·270·69], p = 0·005), e entre pretos versus brancos/asiáticos (aOR 0·51 [IC95% 0·310·85], p = 0·040). Interpretação: Entre brasileiros HSH elegíveis para a PrEP, o conhecimento do HIV foi associado ao aumento do uso da PrEP e homonegatividade internalizada com a diminuição do uso.
RESUMO
Introdução: O número de usuários da profilaxia pré-exposição (PrEP) no Brasil continua baixo, apesar do acesso gratuito pelo Sistema Único de Saúde. Exploramos as associações entre conhecimento sobre HIV e homonegatividade internalizada com o uso de PrEP entre homens que fazem sexo com homens (HSH) elegíveis para PrEP. Métodos: Brasileiros usuários do Hornet completaram uma pesquisa seccional online em fevereiro-março de 2020. Foram incluídos homens cis ≥18 anos, que reportaram sexo recente com homens e elegíveis para PrEP. O desfecho principal foi uso de PrEP, definido por: "Estou atualmente tomando PrEP." Os principais preditores incluíram escalas de Conhecimento em HIV/aids (HIV-KA) e de Reações à Homossexualidade (RHS); escores mais altos indicam maior conhecimento e maior homonegatividade internalizada, respectivamente. As escalas foram padronizadas para análise. Associações com uso da PrEP foram estimadas usando razões de chances ajustadas (aOR) com intervalos de confiança de 95% (IC95%). Resultados: Entre 2.398 HSH elegíveis para PrEP, 370 (15,4%) relataram o uso atual de PrEP. Maior conhecimento em HIV/AIDS foi associado a maior chance de uso de PrEP (aOR 1·70 [IC 95% 1·412·04], p < 0·001), e maior homonegatividade internalizada com menor chance de uso de PrEP (aOR 0·83 [95% IC 0·730·96], p = 0·010). Uso de PrEP foi menor entre HSH de 1824 vs. 40+ anos (aOR 0·43 [IC95%:0·270·69], p = 0·005), e entre pretos versus brancos/asiáticos (aOR 0·51 [IC95% 0·310·85], p = 0·040). Interpretação: Entre brasileiros HSH elegíveis para a PrEP, o conhecimento do HIV foi associado ao aumento do uso da PrEP e homonegatividade internalizada com a diminuição do uso.